Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Nov 22:15:1483903.
doi: 10.3389/fgene.2024.1483903. eCollection 2024.

Case Report: Atypical motor development in a patient with the mosaic form of Down syndrome and spinal muscular atrophy type 2- long-term observation

Affiliations
Case Reports

Case Report: Atypical motor development in a patient with the mosaic form of Down syndrome and spinal muscular atrophy type 2- long-term observation

Ewa Gajewska et al. Front Genet. .

Abstract

A boy is presented in whom Down Syndrome mosaicism and spinal muscular atrophy by overlapping clinical symptoms delayed the diagnosis and caused complicated motor development. The boy from the first pregnancy was delivered vaginally, week 37, Apgar 10, birth weight 3,650 g. The mother, aged 30, had no family history of Down Syndrome or neuromuscular diseases. Primary diagnosis at the age of 3 weeks: unbalanced male karyotype -mos 47, XY+21 [22]/46, XY. At 20 months, the parents observed the disappearance of the high kneeling function and asked for a neurologist's consultation. The neurological examination showed symmetrically reduced muscle tone and symmetrically weakened knee and ankle tendon reflexes. The physiotherapeutic assessment revealed a symmetrical weakening of muscle strength and hand tremor (features characteristic of patients with spinal muscular atrophy). The final diagnosis, set at the age of 27 months, was thus the mosaic form of Down Syndrome and spinal muscular atrophy type 2.

Keywords: Down syndrome; motor development; physiotherapy; postural control; spinal muscular atrophy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

References

    1. Bieniaszewska A., Sobieska M., Gajewska E. (2022). Prospective analysis of functional and structural changes in patients with spinal muscular atrophy—a pilot study. Biomedicines 10 (12), 3187. 10.3390/biomedicines10123187 - DOI - PMC - PubMed
    1. Chong L. C., Gandhi G., Lee J. M., Yeo W. W. Y., Choi S. B. (2021). Drug discovery of spinal muscular atrophy (SMA) from the computational perspective: a comprehensive review. IJMS 22 (16), 8962. 10.3390/ijms22168962 - DOI - PMC - PubMed
    1. Dubowitz V. (2019). Spinal muscular atrophy revisited. Neuromuscul. Disord. 29 (6), 413–414. 10.1016/j.nmd.2019.06.008 - DOI - PubMed
    1. Dunaway S., Montes J., Ryan P. A., Montgomery M., Sproule D. M., De Vivo D. C. (2012). Spinal muscular atrophy type III: trying to understand subtle functional change over time--a case report. J. Child. Neurol. 27 (6), 779–785. 10.1177/0883073811425423 - DOI - PubMed
    1. Finkel R., Bertini E., Muntoni F., Mercuri E. ENMC SMA Workshop Study Group (2015). 209th ENMC international workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7-9 november 2014, heemskerk, The Netherlands. Neuromuscul. Disord. 25 (7), 593–602. 10.1016/j.nmd.2015.04.009 - DOI - PubMed

Publication types

LinkOut - more resources